An Effective Approach to Prevent Immune Rejection of Human ESC-Derived Allografts
Scientists established knockin human embryonic stem cells (hESCs) that constitutively express CTLA4-Ig and PD-L1 before and after differentiation, denoted CP hESCs. They then demonstrated that allogenic CP hESC-derived teratomas, fibroblasts, and cardiomyocytes are immune protected in humanized mice, while cells derived from parental hESCs are effectively rejected. [Cell Stem Cell]
Abstract|Press Release|Graphical Abstract
The Circulating Proteinase Inhibitor α-1 Antitrypsin Regulates Neutrophil Degranulation and Autoimmunity
Researchers investigated the ability of serum α-1 antitrypsin (AAT) to control tumor necrosis factor-α (TNF-α) biosynthesis and signaling in neutrophils and assessed whether AAT deficiency is a TNF-α-related disease. In vitro studies demonstrated that serum AAT coordinates TNF-α intracellular signaling and neutrophil degranulation of tertiary and secondary granules via modulation of ligand-receptor interactions. [Sci Transl Med]
Abstract
Lysine Deacetylase Inhibition Prevents Diabetes by Chromatin-Independent Immunoregulation and β-Cell Protection
The authors demonstrated that the clinically well-tolerated lysine deacetylase inhibitors vorinostat and givinostat revert diabetes in the nonobese diabetic mouse model of type 1 diabetes and counteract inflammatory target cell damage by a mechanism of action consistent with transcription factor-rather than global chromatin-hyperacetylation. Vorinostat treatment increased the frequency of functional regulatory T-cell subsets and their transcription factors Gata3 and FoxP3 in parallel to a decrease in inflammatory dendritic cell subsets and their cytokines IL-6, IL-12, and TNF-α. [Proc Natl Acad Sci USA]
Abstract|Press Release
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Bellicum Pharmaceuticals, Inc. announced that it has completed a second and final closing of its Series B financing, securing an additional $14.7 million and bringing the total raised in the round to $34.4 million. The funding will be used to expand clinical development of Bellicum’s lead cellular immunotherapy product candidates. [Bellicum Pharmaceuticals, Inc.]
Press Release
TxCell Enters Col-Treg into Full Development for the Rare Disease Autoimmune Uveitis
TxCell SA announced it has initiated a full development program with Col-Treg for the treatment of Autoimmune Uveitis. Col-Treg is TxCell’s second therapeutic candidate from its ASTrIA platform after Ovasave®, TxCell’s lead autologous antigen-specific regulatory T-cell-based immunotherapy. [TxCell SA]
Press Release
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have
we missed an important article or publication in Immune Regulation News? Click here to submit!
Comments or Suggestions? Submit your feedback here.
